# Prevention of Asthma With Levocetirizine (36 Month Treatment) in Young Children Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and House Dust Mite and Having Completed the Previous EPAAC Trial (NCT00152464)

> **NCT00160563** · PHASE3 · TERMINATED · sponsor: **UCB Pharma** · enrollment: 207 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** LEVOCETIRIZINE
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00160563
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-06
- **Primary completion:** 2006-03
- **Final completion:** 2006-03
- **Target enrollment:** 207 (ACTUAL)
- **Why stopped:** The predecessor study A00309 (NCT00152464) did not show statistical significance in time to onset of asthma between the levocetirizine and placebo groups.
- **Last updated:** 2015-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00160563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00160563, "Prevention of Asthma With Levocetirizine (36 Month Treatment) in Young Children Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and House Dust Mite and Having Completed the Previous EPAAC Trial (NCT00152464)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00160563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*